粪便类药物的存废之争
摘要
关键词
全文:
PDF参考
[1]李大勤.建议淘汰粪便类中药[J].河南中医药学刊,1996,11(2):63-64
[2]许建峰,王英絮,田彤,张彦明,武永利,林瑞珠.中药金汁与FMT的异同[J].中华中医药杂志,2017,32 (08):3414-3416.
[3]倪士峰,刘惠,刘昱,吴一飞,赵桂仿.“粪便”类中药的研究现状[J].中医药通报,2008,(05):64-66.
[4]凌奂.本草害利[M].北京:中医古籍出版社,1982.
[5]马王堆汉墓.五十二病方[M].北京:文物出版社,1979.
[6]葛洪.肘后备急方[M].北京:中国中医药出版社,2016.
[7]张仲景.伤寒杂病论[M].广西:广西人民出版社,1960.
[8]陶弘景.本草经集注[M].北京:人民卫生出版社,1994.
[9]叶天士.温热论[M].长沙:学院出版社,2021.
[10]证类本草[M].北京:中国医药科技出版社,2021.
[11]李时珍.本草纲目[M].长沙:学院出版社,2021.
[12]陈存仁.中国药学大辞典[M].北京:人民卫生出版社,1956
[13]于智敏,周超凡.论粪便类中药利大于弊[J].中国中医药杂志,1995,20(12):759-761
[14]周超凡.关于粪便类药物的思考[J].世界中医药,2010,5(02):138-140
[15]胡小松.五灵脂中菌群种类及其生物转化作用初步研究[D].北京:北京中医药大学,2021.
[16]谢冠群,朱飞叶,侯晓丽,范永升.从粪便移植疗法话中医金汁[J].中华中医药杂志,2015,30(06):1907-1909.
[17]胡纯仙,李树婷.从“尿疗”引生的国家一类抗癌新药——尿多酸肽(喜滴克)[J].抗癌之窗,2010,(05):74.
[18]Kenneally C, Murphy CP, Sleator RD, Culligan EP. The urinary microbiome and biological therapeutics: Novel therapies for urinary tract infections. Microbiol Res. 2022 Jun;259:127010.
[19]向丽园,张发明.FMT在艰难梭菌感染治疗中的应用[J].临床荟萃,2018,33(05):385-389.
[20].Luo H,Cao G, Luo C,Tan D,Vong CT, Xu Y,Wang S, Lu H,Wang Y,Jing W.Emerging pharmacotherapy for inflammatory bowel diseases. Pharmacol Res. 2022 Apr;178:106146.
[21].Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW,Tan B, Wang XY.Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018 Jan 7;24(1):5-14.
[22]. Antushevich H. Fecal microbiota transplantation in disease therapy. Clin Chim Acta. 2020 Apr;503:90-98.
[23]Schöler D, Schnabl B. The role of the microbiome in liver disease. Curr Opin Gastroenterol. 2024 May 1;40(3):134-142.
[24]. Green JE, Davis JA, Berk M, Hair C, Loughman A, Castle D, Athan E, Nierenberg AA, Cryan JF, Jacka F, Marx W. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes. 2020 Nov 9;12(1):1-25.
[25]魏佳华,于同月,仝小林.五灵脂的临床应用及其用量探究[J].长春中医药大学学报,2022,38(10):1076-1079.
[26]许珍.人尿激酶粗制品生产质量控制与提取工艺研究[D].扬州:扬州大学,2021.
[27]陈俊杰.人尿液外泌体的蛋白质组及糖基化蛋白质组鉴定研究[D].东北:东北大学,2021.
[28]李惠福,钟克庭,陈远飞.人尿促性激素的简易提取法[J].中国药学杂志,1985,(10):585-591
[29]倪士峰,刘惠,刘昱,吴一飞,赵桂仿.“粪便”类中药的研究现状[J].中医药通报,2008,(05):64-66.
Refbacks
- 当前没有refback。